Evidence map›Paper›PMID 40338301›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Head-to-head comparison of peptide-based and nanobody-based radiotracers in detecting PD-L1 expression in non-small cell lung cancer.

Yanfei Wu, Hao Wang, Yue Gu, You Zhang, Guanglei Li, Yuan Huang, Min Cao, Xiaofeng Chen, Yihui Guan, Dong Xu and 2 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yanfei Wu *Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Hao Wang *Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Yue Gu *Central Research Institute, United Imaging Healthcare Group Co., Ltd, Shanghai, China.
You Zhang *Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
Guanglei LiDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Yuan HuangRehabilitation Department, Huashan Hospital, Fudan University, Shanghai, China.
Min CaoDepartment of Thoracic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
Xiaofeng ChenDepartment of Thoracic Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Yihui GuanDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
Dong XuDepartment of Thoracic Surgery, Huashan Hospital, Fudan University, Shanghai, China. dr_xudong1987@126.com.
Weijun WeiDepartment of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China. wwei@shsmu.edu.cn.
Fang XieDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China. fangxie@fudan.edu.cn.ORCID 0000-0003-2667-281X

Funding

Shanghai Municipal Key Clinical Specialty shslczdzk03402
6 · The paper itself

Abstract

backgroundImmunotherapy based on programmed cell death protein receptor 1 and its ligand (PD-1/PD-L1) has become an important method for treating non-small cell lung cancer (NSCLC). Peptide-based and nanobody-based PET tracers offer potential advantages in PD-L1 detection, yet their comparative tumor uptake and biodistribution remain unclear. This study aimed to evaluate and compare [

methodsTen patients diagnosed with NSCLC underwent [

resultsDOTA-WL12 and NOTA-RW102 exhibited favorable binding affinities with PD-L1, with equilibrium dissociation constant (K

conclusionThe uptake of peptide-based [

Indexed as

B7-H1 AntigenCarcinoma, Non-Small-Cell LungGene Expression Regulation, NeoplasticLung NeoplasmsPeptidesSingle-Domain AntibodiesAgedFemaleGallium RadioisotopesHeterocyclic Compounds, 1-RingHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyRadioactive TracersTissue DistributionB7-H1 AntigenCD274 protein, humanGallium RadioisotopesHeterocyclic Compounds, 1-RingPeptidesRadioactive TracersSingle-Domain AntibodiesNanobodyNSCLCPD-L1PeptidePET/CT

Identifiers

PMID40338301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.